Cargando…
Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies
Immune-modulating medications for inflammatory bowel diseases (IBDs) have been associated with suboptimal vaccine responses. There are conflicting data with SARS-CoV-2 vaccination. We therefore assessed SARS-CoV-2 vaccine immunogenicity at 2 weeks after second mRNA vaccination in 29 patients with IB...
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038482/ https://www.ncbi.nlm.nih.gov/pubmed/35347100 http://dx.doi.org/10.14309/ctg.0000000000000484 |
| _version_ | 1784693931952308224 |
|---|---|
| author | Boland, Brigid S. Goodwin, Benjamin Zhang, Zeli Bloom, Nathaniel Kato, Yu Neill, Jennifer Le, Helen Tysl, Tiffani Collins, Angelina E. Dulai, Parambir S. Singh, Siddharth Nguyen, Nghia H. Grifoni, Alba Sette, Alessandro Weiskopf, Daniela Chang, John T. Dan, Jennifer M. |
| author_facet | Boland, Brigid S. Goodwin, Benjamin Zhang, Zeli Bloom, Nathaniel Kato, Yu Neill, Jennifer Le, Helen Tysl, Tiffani Collins, Angelina E. Dulai, Parambir S. Singh, Siddharth Nguyen, Nghia H. Grifoni, Alba Sette, Alessandro Weiskopf, Daniela Chang, John T. Dan, Jennifer M. |
| author_sort | Boland, Brigid S. |
| collection | PubMed |
| description | Immune-modulating medications for inflammatory bowel diseases (IBDs) have been associated with suboptimal vaccine responses. There are conflicting data with SARS-CoV-2 vaccination. We therefore assessed SARS-CoV-2 vaccine immunogenicity at 2 weeks after second mRNA vaccination in 29 patients with IBD compared with 12 normal healthy donors. We observed reduced humoral immunity in patients with IBD on infliximab. However, we observed no difference in humoral and cell-mediated immunity in patients with IBD on infliximab with a thiopurine or vedolizumab compared with normal healthy donors. This is the first study to demonstrate comparable cell-mediated immunity with SARS-CoV-2 vaccination in patients with IBD treated with different immune-modulating medications. |
| format | Online Article Text |
| id | pubmed-9038482 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Wolters Kluwer |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90384822022-04-26 Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies Boland, Brigid S. Goodwin, Benjamin Zhang, Zeli Bloom, Nathaniel Kato, Yu Neill, Jennifer Le, Helen Tysl, Tiffani Collins, Angelina E. Dulai, Parambir S. Singh, Siddharth Nguyen, Nghia H. Grifoni, Alba Sette, Alessandro Weiskopf, Daniela Chang, John T. Dan, Jennifer M. Clin Transl Gastroenterol Brief Report Immune-modulating medications for inflammatory bowel diseases (IBDs) have been associated with suboptimal vaccine responses. There are conflicting data with SARS-CoV-2 vaccination. We therefore assessed SARS-CoV-2 vaccine immunogenicity at 2 weeks after second mRNA vaccination in 29 patients with IBD compared with 12 normal healthy donors. We observed reduced humoral immunity in patients with IBD on infliximab. However, we observed no difference in humoral and cell-mediated immunity in patients with IBD on infliximab with a thiopurine or vedolizumab compared with normal healthy donors. This is the first study to demonstrate comparable cell-mediated immunity with SARS-CoV-2 vaccination in patients with IBD treated with different immune-modulating medications. Wolters Kluwer 2022-03-28 /pmc/articles/PMC9038482/ /pubmed/35347100 http://dx.doi.org/10.14309/ctg.0000000000000484 Text en © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Brief Report Boland, Brigid S. Goodwin, Benjamin Zhang, Zeli Bloom, Nathaniel Kato, Yu Neill, Jennifer Le, Helen Tysl, Tiffani Collins, Angelina E. Dulai, Parambir S. Singh, Siddharth Nguyen, Nghia H. Grifoni, Alba Sette, Alessandro Weiskopf, Daniela Chang, John T. Dan, Jennifer M. Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies |
| title | Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies |
| title_full | Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies |
| title_fullStr | Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies |
| title_full_unstemmed | Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies |
| title_short | Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies |
| title_sort | preserved sars-cov-2 vaccine cell-mediated immunogenicity in patients with inflammatory bowel disease on immune-modulating therapies |
| topic | Brief Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038482/ https://www.ncbi.nlm.nih.gov/pubmed/35347100 http://dx.doi.org/10.14309/ctg.0000000000000484 |
| work_keys_str_mv | AT bolandbrigids preservedsarscov2vaccinecellmediatedimmunogenicityinpatientswithinflammatoryboweldiseaseonimmunemodulatingtherapies AT goodwinbenjamin preservedsarscov2vaccinecellmediatedimmunogenicityinpatientswithinflammatoryboweldiseaseonimmunemodulatingtherapies AT zhangzeli preservedsarscov2vaccinecellmediatedimmunogenicityinpatientswithinflammatoryboweldiseaseonimmunemodulatingtherapies AT bloomnathaniel preservedsarscov2vaccinecellmediatedimmunogenicityinpatientswithinflammatoryboweldiseaseonimmunemodulatingtherapies AT katoyu preservedsarscov2vaccinecellmediatedimmunogenicityinpatientswithinflammatoryboweldiseaseonimmunemodulatingtherapies AT neilljennifer preservedsarscov2vaccinecellmediatedimmunogenicityinpatientswithinflammatoryboweldiseaseonimmunemodulatingtherapies AT lehelen preservedsarscov2vaccinecellmediatedimmunogenicityinpatientswithinflammatoryboweldiseaseonimmunemodulatingtherapies AT tysltiffani preservedsarscov2vaccinecellmediatedimmunogenicityinpatientswithinflammatoryboweldiseaseonimmunemodulatingtherapies AT collinsangelinae preservedsarscov2vaccinecellmediatedimmunogenicityinpatientswithinflammatoryboweldiseaseonimmunemodulatingtherapies AT dulaiparambirs preservedsarscov2vaccinecellmediatedimmunogenicityinpatientswithinflammatoryboweldiseaseonimmunemodulatingtherapies AT singhsiddharth preservedsarscov2vaccinecellmediatedimmunogenicityinpatientswithinflammatoryboweldiseaseonimmunemodulatingtherapies AT nguyennghiah preservedsarscov2vaccinecellmediatedimmunogenicityinpatientswithinflammatoryboweldiseaseonimmunemodulatingtherapies AT grifonialba preservedsarscov2vaccinecellmediatedimmunogenicityinpatientswithinflammatoryboweldiseaseonimmunemodulatingtherapies AT settealessandro preservedsarscov2vaccinecellmediatedimmunogenicityinpatientswithinflammatoryboweldiseaseonimmunemodulatingtherapies AT weiskopfdaniela preservedsarscov2vaccinecellmediatedimmunogenicityinpatientswithinflammatoryboweldiseaseonimmunemodulatingtherapies AT changjohnt preservedsarscov2vaccinecellmediatedimmunogenicityinpatientswithinflammatoryboweldiseaseonimmunemodulatingtherapies AT danjenniferm preservedsarscov2vaccinecellmediatedimmunogenicityinpatientswithinflammatoryboweldiseaseonimmunemodulatingtherapies |